AbbVie Reports Phase 3 U-ACHIEVE Results for Rinvoq in Ulcerative Colitis

AbbVie today announced results from the Phase 3 U-ACHIEVE trial evaluating Rinvoq (upadacitinib) in patients with moderately to severely active ulcerative colitis. The trial met its primary endpoint, demonstrating a significantly higher rate of clinical remission compared to placebo at week 8. These results led to FDA approval of Rinvoq for ulcerative colitis.